Friday, Sep 30, 2022

We will intervene to make critical drugs affordable,says govt

Bayer prices the drug at Rs 2.8 lakh for a month’s dose in India

The government today asserted India would invoke the flexibility it had under the WTO agreement on Trade Related Intellectual Property Rights (TRIPs) for compulsory licensing of patented drugs to ensure availability of life saving drugs at affordable prices to its people.

The Controller General of Patents,Designs and Trademarks had on Monday allowed Hyderabad-headquartered Natco Pharma to manufacture a generic version of Nexawar or Sorafenib,a cancer drug patented by Bayer in 2008.

Commerce and Industry Minister Anand Sharma,under whose administrative purview the controller functions,told The Indian Express,“India had not invoked it so far. This is the first time. But Brazil did it in 2007 for an antiretroviral drug patented by Merck.”

India would resort to compulsory licensing of patented drugs if it is absolutely necessary for the public good,he added.

Subscriber Only Stories
Shashi Tharoor: ‘I don’t think everyone who voted BJP in 2014...Premium
Ahead of Centre’s ban, chorus from Sangh, affiliatesPremium
Volatile INR still relatively stable; what now?Premium
Hindu-Muslim violence in the UK: Revisiting LeicesterPremium

Bayer prices the drug at Rs 2.8 lakh for a month’s dose (120 tablets) in India. The controller’s order allows Natco to sell a generic version at a fraction of the cost — Rs 8,800 a month.

The new controller general of patents,Chaitanya Prasad,who took charge today,said his predecessor P H Kurian took the decision for the larger public good. Asked if the order would prompt other companies to apply for compulsory delicensing,he said,“It’s possible that some may come. We will have to wait and see. There’re no indications as of now.”

First published on: 14-03-2012 at 03:17:32 am
Next Story

Fearing March 15 as last date,jobless swamp exchanges

Latest Comment
Post Comment
Read Comments